Patients with definite UA/NSTEMI at medium or high risk and in whom an initial invasive strategy is selected (Appendix 6) should receive dual antiplatelet therapy on presentation.13,16,45,69 (Level of Evidence: A) Aspirin should be initiated on presentation.59,61 66 (Level of Evidence: A) The choice of a second antiplatelet therapy to be added to aspirin on presentation includes 1 of the following (note that there are no data for therapy with 2 concurrent P2Y12 receptor inhibitors, and this is not recommended in the case of aspirin allergy): modified (included ticagrelor). Before PCI: Clopidogrel13,16 (Level of Evidence: B); or Ticagrelor 9 (Level of Evidence: B); or An IV GP IIb/IIIa inhibitor.45,50,51,70,71 (Level of Evidence: A) IV eptifibatide and tirofiban are the preferred GP IIb/IIIa inhibitors.50,51 (Level of Evidence: B) At the time of PCI: Clopidogrel if not started before PCI13,16 (Level of Evidence: A); or Prasugrel*7 (Level of Evidence: B); or Ticagrelor 9 (Level of Evidence: B); or An IV GP IIb/IIIa inhibitor.46,50,51 (Level of Evidence: A) 4. For UA/NSTEMI patients in whom an initial conservative (ie, noninvasive) strategy is selected, clopidogrel or ticagrelor (loading dose followed by daily maintenance dose) should be added to aspirin and anticoagulant therapy as soon as possible after admission and administered for up to 12 months.9,10,13 (Level of Evidence: B) modified (included ticagrelor and changed duration of therapy to up to 12 months ). 5. 